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Abstract
Swine influenza viruses (SIVs), the causal agents of swine influenza, are not only important
to control due to the economic losses in the swine industry, but also can be pandemic patho-
gens. Vaccination is one of the most relevant strategies to control and prevent influenza
infection. Current human vaccines against influenza induce strain-specific immunity and
annual update is required due to the virus antigenic shift phenomena. Previously, our group
has reported the use of conserved hemagglutinin peptides (HA-peptides) derived from H1-
influenza virus as a potential multivalent vaccine candidate. Immunization of swine with
these HA-peptides elicited antibodies that recognized and neutralized heterologous influ-
enza viruses in vitro and demonstrated strong hemagglutination-inhibiting activity. In the
present work, we cloned one HA-peptide (named NG34) into a plasmid fused with cytotoxic
T lymphocyte-associated antigen (CTLA4) which is a molecule that modifies T cell activation
and with an adjuvant activity interfering with the adaptive immune response. The resulting
plasmid, named pCMV-CTLA4-Ig-NG34, was administered twice to animals employing a
needle-free delivery approach. Two studies were carried out to test the efficacy of pCMV-
CTLA4-Ig-NG34 as a potential swine influenza vaccine, one in seronegative and another
in seropositive pigs against SIV. The second one was aimed to evaluate whether pCMV-
CTLA4-Ig-NG34 vaccination would overcome maternally derived antibodies (MDA). After
immunization, all animals were intranasally challenged with an H3N2 influenza strain. A
complete elimination or significant reduction in the viral shedding was observed within the
first week after the challenge in the vaccinated animals from both studies. In addition, no
challenged heterologous virus load was detected in the airways of vaccinated pigs. Overall,
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it is suggested that the pCMV-CTLA4-Ig-NG34 vaccine formulation could potentially be
used as a multivalent vaccine against influenza viruses.
Introduction
Influenza-like disease in pigs started occurring in both United States and Europe in connec-
tion with the human influenza pandemic in 1918. Proof of this is the close relationship
between the early H1N1 swine viruses with the human influenza virus of 1918, as determined
by genetic analyses [1].
The influenza disease in pigs, although rarely fatal, has a high morbidity close to 100% [2].
The etiological agents of the disease, Swine influenza viruses (SIVs), are considered one of the
major causes of acute respiratory disease outbreaks in swine herds [3,4]. Together with the
well-known postulate that pigs act like “mixing vessels” of new reassortant influenza viruses
[5], it may be of vital importance to develop effective vaccines that can confer protection
against a broad umbrella of different SIV subtypes.
SIVs co-circulating in European swine are from the subtypes H1N1 (SwH1N1), H3N2
(SwH3N2) and H1N2 (SwH1N2) [6,7] that are also equivalent to the more prevalent subtypes
in North America [8]. Thus, in line with the circulating subtypes in the swine population [6–
8], current commercial vaccines available for pigs consist of two or three inactivated SIV
strains belonging to the aforementioned subtypes. Vaccines are commonly administered in
pregnant sows to stimulate passive antibody transfer via colostrum. Regrettably, protection
with these commercial vaccines is only achieved when the strain either closely or completely
matches with the challenged virus [9–13]. The reported lack of protection against divergent
strains is thought to be associated with the poor stimulation of the mucosal and cellular immu-
nity provided by inactivated-typed vaccines [11,14,15]. It is thus fundamental to seek new vac-
cine strategies eliciting robust immune response and protection against drifted or emerging
strains occurring from antigenic drift or antiviral shift, respectively.
The new emergent vaccine formulas must take maternally derived antibodies (MDA) inter-
ference into account since the presence of MDA inhibit/neutralize current vaccines [16,17].
Even though optimal vaccination of animals should begin at the time of disappearance of
maternal antibodies, this approach is often unfeasible due to a high degree of variability in
antibody titers between individuals [18]. Similarly, inactivated-typed vaccines may pose draw-
backs in piglets with MDA by suppression of the antibody responses [19–21], and because
they may enhance respiratory diseases upon influenza infection [22,23] or cause an aggravated
pneumonia called vaccine associated enhanced respiratory disease (VAERD) [24]. Thus, an
additional aim of this work was to evaluate the capacity of the vaccine to provide protection
against a heterologous influenza virus strain to individuals with MDA.
Our group has previously reported the use of an HA1-based peptide (NF-34) in pigs as
potential vaccine [25]. Partial virus clearance after an intranasal challenge with the homolo-
gous pH1N1 (pandemic swine-origin A/Catalonia/63/2009 H1N1 IV) influenza virus was
observed along with a strong humoral and T-cell response in animals vaccinated with the NF-
34 HA-peptide. Although NF-34 HA showed concomitant detection of antibody response it
did not totally correlate with neutralizing activity [25]. In the present study, NF-34 peptide has
been modified (named NG34) and employed in a DNA vaccine approach (pCMV-CTLA4-Ig-
NG34). In addition, to ameliorate safety and large-scale vaccination approaches, a needle-free
intradermal administration technique (IDAL device) was applied.
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The research objectives were two-fold in two different swine experiments depending on the
initial presence/absence of MDA. Firstly, to assess vaccine efficacy against a heterologous SIV
isolate in seronegative animals (SwH3N2) and, secondly, to investigate whether farm animals
could clear a heterologous virus challenge, thus overcoming MDA obstacles.
In the present work, we demonstrated that immunization of seronegative pigs with
pCMV-CTLA4-Ig-NG34 antigen formulation induced neutralizing antibodies that inhibited
hemagglutination of a heterologous SIV. Moreover, immunized conventional farm pigs (both
the influenza virus seropositive and seronegative) were fully or partially protected against a
heterologous influenza virus challenge as they either completely eliminated or significantly
reduced virus secretion and cleared the virus from the respiratory airways.
Materials and methods
Ethics statement
All animal studies presented in this work were approved by IRTA’s Ethics Committee for Ani-
mal Experimentation and the Animal Experimentation Commission from the Catalonia Gov-
ernment (Spain) in compliance with the Directive, EU 63/2010, the Spanish Legislation (RD
53/2013) and the Catalan Law 5/1995 and Decree 214/1997. Treatment with anesthetics or
analgesics was not considered because animals did not suffer from the disease and/or experi-
mental manipulation.
Experimental design
The results presented in this manuscript are representative of two almost identical experimen-
tal studies performed in swine, whose outlines are described in Fig 1. In both studies, animals
were observed daily during the course of the experiments by monitoring for flu-like clinical
signs and rectal temperature profiles; and the severity of clinical signs was assessed from 0 to 3
according to a previously described scoring [26]. Animals received water and food ad libitum.
In a first study, 10 five-to-six week-old, Influenza A virus seronegative, Yorkshire x Land-
race pigs were used. Animals were housed, vaccinated and challenged in the animal Biosafety
Level 3 (BSL-3) facility at CReSA (Barcelona, Spain). Animals were randomly distributed
into two groups of 5 animals each (Group A = non-vaccinated pigs, animals 1–5; Group
B = vaccinated pigs, animals 6–10). After an acclimatization period of 5 days, five pigs were
vaccinated twice with an interval of 3 weeks by injecting the final plasmid formulation using a
needle-free device, Intra Dermal Application of Liquids, (IDAL MSD Animal Health), on the
dorsal side of the back of each animal as previously described [27]. The final plasmid formula-
tion used for immunization consisted of 600 μg DNA construct pCMV-CTLA4-Ig-NG34
(applied in 3 shots/vaccination) mixed with Diluvac Forte from MSD Animal Health (1:1 v/v).
The remaining five pigs were sham-vaccinated (control group). Two weeks after the second
vaccination, both groups received an intranasal challenge of a SIV H3N2 isolate at a concentra-
tion of 106 TCID50/mL in 3 mL saline solution into each animal (1.5 mL/nostril) by using the
MAD device (Intranasal Mucosal Atomizing Device, Teleflex). Euthanasia and necropsies
were carried out 7 days post-inoculation (dpi). Sera from all individuals were collected previ-
ous to each immunization, before the challenge, and at 7 dpi. Nasal swabs were collected before
challenge and at 3, 5 and 7 dpi. Eventually, lung tissues were obtained and fixed by immersion
in 10% neutral buffer formalin to perform the histopathological analysis.
The second study was performed applying identical conditions as those of the first study,
albeit with influenza A virus seropositive animals. The goal of this second study was to simu-
late conditions generally occurring under usual conventional farm conditions. For that reason,
animals were vaccinated in the farm and were transported to BSL-3 facilities for challenge.
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Each group consisted of six animals (Group A = non-vaccinated pigs, animals 1–6; Group
B = vaccinated group, animals 7–14), and three pigs were euthanized at either 7 or 14 dpi.
Sample collection was similar in both studies until day 7, albeit at different times. In this study,
nasal swabs were collected before challenge and at 1, 2, 4 and 7 dpi. Moreover, bronchoalveolar
fluids (BALFs) were collected from the right lung of each pig at the time of euthanasia (7 and
14 dpi).
A complementary study with three SIV-seronegative pigs was performed in order to evalu-
ate the immunogenic effect of the plasmid without the NG34 sequence (empty vector). The
same experimental design as the described for the study 1 was carried out (Fig 1), but animals
were vaccinated with 600μg DNA construct pCMV-CTLA4-Ig. Here, BALFs were also col-
lected at 7 dpi.
Cells, virus and antigens
Madin-Darby Canine Kidney (MDCK, ATCC CCL-34) cells were cultured in Dulbecc’s Modi-
fied Eagle Medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1% penicillin/
streptomycin and 1% L-glutamine. The cell cultures were kept at 37˚C with 5% CO2 atmo-
sphere in a humidified incubator.
SwH3N2 (A/swine/Spain/003/2010 H3N2 IV) [GenBank JQ319724 and JQ319726] influ-
enza virus was used in this study for the intranasal challenge. The 50% tissue culture infectious
dose (TCID50) was calculated in MDCK cells according to Reed and Muench method [28].
The sequence identity between antigen of interest (NG34) and challenge virus, SwH3N2,
used in this study is of 26% (Table 1).
Fig 1. Experimental outline of two studies. (A) 1st study outline: seronegative pigs against SIV were vaccinated at 0 and 21 days,
and challenged at 42 days. Sera were collected each pre-vaccination, pre-challenge and at necropsy day (7 dpi), as indicated. Lung
tissues at 7 dpi. Nasal swabs collection took place at challenge day and at all days indicated in the figure. (B) 2nd study outline:
seropositive pigs against SIV, vaccinated at 0 and 21 days, and challenged at 42 days. Sera were collected each pre-vaccination, pre-
challenge and necropsy days (7 and 14 dpi). Lung tissues were obtained at 7 and 14 dpi. In this case, bronchoalveolar fluids (BALFs)
were also collected at 7 and 14 dpi. Nasal swabs collection took place at challenge day and at all days indicated in the figure. Dpi, days
post-inoculation; NS, nasal swabs.
https://doi.org/10.1371/journal.pone.0212431.g001
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Purified hemaggluinins of A/California/04/09(H1N1)pdm09 and A/Aichi/2/1968 (H3)
were purchased from SinoBiological (Sino Biological, cat. no. 40340-V08B and 11707-V08H;
respectively) and were used as antigens.
Sample collection
Nasal swabs collected at predetermined time points were placed in 500 μL of PBS with antibi-
otics (100 U/mL penicillin and 0.1 mg/mL streptomycin). Serum samples were obtained
from the jugular vein. After necropsy, BALFs from animals from the second study were also
obtained by introducing 150 mL of PBS into the right lung of each pig, massaged gently and
recollected into 50 mL falcon tubes [29]. BALFs were further centrifuged to remove cells. All
supernatant samples were stored at -80˚C until analysis.
Pathological assessment
Complete necropsies were performed, with special emphasis on macroscopic examination of
lung parenchyma. Moreover, samples from apical, medial and cranial part of diaphragmatic
pulmonary lobes were taken and fixed by immersion in 10% buffered formalin. Lung tissues
were then embedded in paraffin, cut in 5 μm sections, stained in hematoxylin and eosin, and
the severity degree of broncho-interstitial pneumonia was scored in a blinded fashion by a sin-
gle pathologist using established criteria [30].
Plasmid synthesis
Two amino acids were replaced from the original HA1-based peptide (NF-34) to design the
NG34 peptide (Table 2). NG34 peptide derives from the HA1 protein of the pH1N1 A/Catalo-
nia/63/2009 strain [GenBank: ACS36215] and was theoretically predicted by the Informational
Spectrum Method (ISM), and mapped within the flanking region of the HA1. In order to
enhance immunogenicity, the NG34 peptide sequence was reverse-translated and cloned into
an expression vector encoding human IgG fused with the extracellular domain of CTLA4.
EndoFree plasmid gigakit (Qiagen, Barcelona, Spain) was used for purification and large-scale
plasmid production. The plasmid was resuspended in sterile saline solution and stored at
-20˚C until use.
Table 1. Amino acid sequence of NG34 (peptide of interest) and the HA from the challenged virus (A/swine/Spain/001/2010 (H3N2).
Antigen Aminoacid sequence
NG34 NSDNGTCYPGDFIDYEELREQLSSVSSFERFEIF
HA from A/swine/Spain/001/2010 (H3N2) KA -FSNCYPYDVPEYTSLRSLIASSGTLEFTNED
The amino acid identity between sequences is depicted in bold.
https://doi.org/10.1371/journal.pone.0212431.t001
Table 2. Amino acid modifications in peptide NF34 to obtain the NG34 peptide.
Peptide Aminoacid sequence
NF34 NSENGTCYPGDFIDYEELREQLSSVSSFEKFEIF
NG34 NSDNGTCYPGDFIDYEELREQLSSVSSFERFEIF
The amino acids differences between sequences are depicted in bold type.
https://doi.org/10.1371/journal.pone.0212431.t002
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Quantitative real time RT-PCR (RT-qPCR)
A TaqMan RT-qPCR was carried out to determine and quantify viral RNA in nasal swabs and
BALFs collected at different time-points during the study. Extraction of RNA was carried out
using NucleoSpin RNA isolation kit (Macherey-Nagel), according to the manufacturer’s instruc-
tions. Primers and probes used in this study, one-step RT-PCR Master Mix Reagents (Applied
Biosystems) and amplification conditions ran in a Fast7500 equipment (Applied Biosystems) to
amplify the conserved fragment of the matrix (M) gene of Influenza viruses are described else-
where [31]. Samples in which fluorescence was undetectable were considered negative.
Subtypic quantitative real time RT-PCR (RT-qPCR)
Viral RNA extracted with NucleoSpin RNA isolation kit (Macherey-Nagel) was tested to
amplify a 95 bp fragment of the hemagglutinin (HA) gene of the challenged strain A/swine/
Spain/003/2010 H3N2 IV. Based on a previous work, specific primers for the subtype H3
were designed [32]: forward 5’-TCCTTTGCCATATCATGCTTTTTG-3, and reverse 5’-
ATGCAAATGTTGCACCTAATGTTG-3’. Specificity of primers was checked utilizing BlastN
[33] through the Influenza Research Database (https://www.fludb.org/brc/blast.spg?method=
ShowCleanInputPage&decorator=influenza) [34]. Real time amplification was performed
employing the Power SYBR Green RNA-to-CT 1-Step Kit (Applied Biosystems, P/N
#4389986) following manufacturer’s indications and using 2 μL of eluted RNA in a total vol-
ume of 20 μL. In brief, for RNA-to-CT 1-Step, the real-time PCR was performed using a
Fast7500 equipment (Applied Biosystems, Foster City, CA, USA) and following cycles: 48˚C
for 30 min (for cDNA synthesis), 95˚C for 10 min (transcriptase inactivation), followed by
95˚C for 15 s and 60˚C for 1 min for 40 cycles. Dissociation curve (melting curve) analyses
were performed employing the parameters of a hot start at 60˚C for 15 s and measuring the
fluorescence every 0.5˚C until 95˚C to confirm specific amplification.
Prior to the setting up of the RT-qPCR, standards were constructed. The amplification condi-
tions for 95 bp of the HA fragment were: a reverse transcription at 50˚C for 30 min; an initial
denaturation reaction at 95˚C for 15 min and 40 PCR-cycles of 94˚C 30 s, 55˚C 1 min and 72˚C
1 min. The obtained HA gene fragment amplicon was cloned into pGEMT vector (Promega
Madison, WI, USA) and transformed by heat shock in Escherichia coli TOP10 competent cells
(Invitrogen, Paisley, UK). The recombinant plasmid was purified using the QIAprep Spin kit
(Qiagen) and quantified by using BioDrop μLITE Spectrophotometer (BioDrop Ltd, Cambridge,
UK). The copy number of recombinant plasmid was calculated as described elsewhere [35] by
following the formula: N (molecules per μL) = (C (DNA) μg/μL/K (fragment size in bp)) ×
182.5 × 1023 (factor derived from the molecular mass per the Avogadro constant). Serial 10-fold
dilutions of known concentration were made and the standard curves were generated using cop-
ies of the recombinant plasmid harbouring the HA gene fragment from the SwH3N2 isolate.
Immunoassays
Virus-antigen specific serum antibodies were detected by ELISA. The influenza virus proteins
used to detect specific antibodies were hemagglutinins (HA) from A/California/04/09(H1N1)
pdm09 and A/Aichi/2/1968(H3N2). Briefly, ELISA plates (Costar, Corning Incorporated)
were coated overnight with 2 μg/mL recombinant influenza hemagglutinin protein antigen in
sodium bicarbonate (50 mM) buffer at 4˚C. Blocking was performed using 3%BSA/PBS for 1
hour at room temperature following washes with 1% Triton X-100/PBS. Sera were diluted
1:100 in the blocking buffer and added to the 96 well plates during an incubation period of 1
hour at room temperature. Then, plates were washed four times and incubated during 30 min-
utes at 37˚C with an anti-pig IgG (whole molecule)-Peroxidase (Sigma) diluted 1:10000 with
Heterosubtypic protection against influenza with pCMV-CTLA4-IG-NG34 in pigs
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the washing buffer. Plates were again washed four times with 1%Triton X-100 PBS and 50 μL
of TMB was added during 8 to 10 minutes for the enzymatic reaction. Finally, the reaction was
stopped by adding 50 μL of 1 N H2SO4. All samples were analyzed in triplicates.
Hemagglutination inhibition assay (HAI)
Hemagglutination inhibition assay was performed following the standard procedures
described previously [25]. Positive and negative sera against H3N2 were purchased from GD
Animal Health (Holland). All sera were analyzed in duplicate.
Statistical analysis
Mean and standard deviations were calculated with Excel 2007 (Microsoft Office) and statisti-
cal differences between the groups were calculated. Briefly, all data obtained were first normal-
ized by Shapiro-Wilk test and later the groups were compared using either the t-test (in case of
normally distributed data), or the Wilcoxon test (in case of non-normally distributed data). All
calculations were carried out using R statistical software (http://cran.r-project.org/).
Results
Clinical and pathological evaluation
In the first study, one animal from unvaccinated group (animal 5) manifested fever at 4 and 7
dpi. From the vaccinated group, fever could be detected in four out of five pigs; three of them
(animals 6, 7 and 8) had fever during days 2, 3 and 4 post-inoculation and one of them (animal
9) on days 3 and 4. No other clinical signs could be observed, except one vaccinated animal
(animal 8), which was coughing at 4 and 5 dpi. Likewise, four out of six animals had fever in
the unvaccinated group (animals 1, 2, 5 and 6) and three out of six from the vaccinated group
(animals 7, 8 and 11) from the second study. Also, one animal from each group was coughing
(animal 1 and 14, both at 3 dpi), and only one vaccinated pig (animal 7) showed apathy and a
loss of weight after the challenge.
In the first study, no differences in the histological lesions in the lung tissues were found at 7
dpi between groups.. No differences in the severity of the histological lesions in the lung tissues
were detected at 7 or 14 dpi in the second study (Table 3). Fig 2 shows different sections of his-
tological lung tissues illustrating the different scoring values (0, 1, 2 or 3). Additionally, besides
the broncho-interstitial pneumonia scoring, other pathological findings were also recorded. In
the first study, animal 8 had bronchiolitis fibrosa obliterans. In the second study, suppurative
bronchopneumonia was present in one animal from the unvaccinated group (animal 1) and in
3 out of 6 animals from the vaccinated group (animals 7, 9 and 10); pig 8 had fibrous pleuritis.
Immunization with pCMV-CTLA4-Ig-NG34 eliminates or significantly
reduces viral shedding
In comparison to the control group, pigs immunized twice with pCMV-CTLA4-Ig-NG34
showed reduced viral shedding within the first week after challenge in both studies (Fig 3).
The mean of genomic equivalent copies (GEC) per mL of the vaccinated pigs was inferior to
the mean of the unvaccinated group at 5 and 7 dpi (Fig 3A). Remarkably, in the first study
(seronegative pigs) from the vaccinated group, in three out of five animals no viral RNA
was detected at 7 dpi. By contrast, viral RNA could be detected in all the five pigs from the
unvaccinated group (p<0.01) (Fig 3A). Moreover, one animal from the unvaccinated group
(animal 3) died, most likely due to a secondary bacterial infection. A reduction in the subtypic
RNA shedding was also observed at 5 dpi in pCMV-CTLA4-Ig-NG34 vaccinated seronegative
Heterosubtypic protection against influenza with pCMV-CTLA4-IG-NG34 in pigs
PLOS ONE | https://doi.org/10.1371/journal.pone.0212431 March 1, 2019 7 / 18
Table 3. Scoring and observations given to each hematoxylin-eosin stained preparation for every single pig of 2nd study.
Vaccine applied Animal identification Necropsy date Broncho-interstitial pneumonia
Unvaccinated 1 7 dpi 2
2 7 dpi 2
5 7 dpi 3
3 14 dpi 0.5
4 14 dpi 1.5
6 14 dpi 0.5
Vaccinated 7 7 dpi 3
9 7 dpi 3
12 7 dpi 2
8 14 dpi 2
10 14 dpi 0.5
11 14 dpi 1
https://doi.org/10.1371/journal.pone.0212431.t003
Fig 2. Representative sections from lung samples fixed with formalin and embedded in paraffin, stained with hematoxylin and
eosin and microscopically evaluated following the scoring system [30] (magnification 100x): (A) scoring 0, (B) scoring 1, (C)
scoring 2, and (D) scoring of 3.
https://doi.org/10.1371/journal.pone.0212431.g002
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animals; however, no virus was detectable in the vaccinated and non-vaccinated animals on
day 7 post-inoculation. (Fig 3B).
In animals with MDA (Study II; seropositive pigs), the mean of GEC per mL was lower at 4
and 7 dpi than those observed in the unvaccinated group. Noteworthy, at 7 dpi, in two out of
the six animals (animals 8 and 9) we could not detect viral RNA (p<0.05) (Fig 3C). Regarding
subtypic viral RNA in MDA positive animals, at 4 and 7 dpi, the mean of GEC per mL, was
lower than those of the unvaccinated group. Furthermore, at 7 dpi viral RNA could not be
detected in two vaccinated animals (Fig 3D).
Results from the vaccinated pigs with pCMV-CTLA4-Ig (empty plasmid) showed that none
of the three pigs were reducing the viral shedding at 7 dpi (S1 Table).
Humoral response to a heterologous influenza virus after
pCMV-CTLA4-Ig-NG34 vaccination
To determine whether the NG34 peptide of H1N1 origin could confer protection against a het-
erosubtypic circulating influenza strain, pigs were challenged with the H3N2 influenza virus
subtype. In addition, attempting to potentially improve the vaccine efficiency, we decided to
Fig 3. Viral detection in nasal swabs samples by RT-qPCR. Mean values of genomic equivalent copies (GEC) per mL obtained
from nasal swabs samples (1st study) collected at 0, 3, 5 and 7 dpi, from seronegative animals and (B) subtypic RT-qPCR results from
the 1st study (C) Mean values of GEC per mL obtained from nasal swabs samples (2nd study) collected at 0, 1, 2, 4 and 7 dpi. from
seropositive animals and (D) subtypic RT-qPCR from the 2nd study. White bars correspond to Group A (unvaccinated group) and
black bars to Group B (pCMV-CTLA4-Ig-NG34 vaccinated group). Dpi, days post-inoculation; Dashed lines indicate the detection
limit of the assays: 1.24 log10GEC/mL. Error bars indicate the mean ± SEM.
https://doi.org/10.1371/journal.pone.0212431.g003
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deliver the antigen in a DNA vaccination approach instead of peptide. Immunogenicity of the
vaccine was examined by the presence of specific antibodies, raised against H1 and H3, and
their ability to HAI against the challenged heterologous virus in the sera collected from vacci-
nated and non-vaccinated animals. Specific immune response in the BALFs collected from
MDA seropositive animals (from the 2nd study) was also examined by testing for specific H1
and H3 antibodies.
pCMV-CTLA4-Ig-NG34 immunization in pigs elicited antibodies that were recognizing
both the HA1 and HA3 hemagglutinin subtypes (Fig 4A and 4B). Increased antibody levels
were observed at 35 post-vaccination days (PVD, pre-challenge) in the vaccinated group (Fig
4A and 4B). The levels of antibodies were higher against HA1 (Fig 4A), since NG34 belongs to
HA1 subtype. Furthermore, sera from all vaccinated animals, collected 7 days after the intrana-
sal challenge with SwH3N2 influenza virus, manifested a potent boost in H3 subtype-specific
antibodies in comparison to non-vaccinated SwH3N2 influenza virus infected control group
(Fig 4B).
Fig 4. Serum antibody HA-specific IgG titers detected in sera and BALFs samples by ELISA test. Mean of serum antibody levels
detected in all individuals at time-points 0, 20 PVD and 35 PVD, and 7 dpi of Groups A and B (A) against HA from A/California/04/
09(H1N1)pdm09, and (B) against HA from A/Aichi/2/1968(H3N2) are shown. Mean of BALFs antibody levels detected in pigs
necropsied at 7 and 14 dpi of Groups A and B (C) against HA from A/California/04/09(H1N1)pdm09, and (D) against HA from A/
Aichi/2/1968(H3N2). White circles/bars designate group A (unvaccinated group), and black squares/bars designate group B
(pCMV-CTLA4-Ig-NG34 vaccinated group). OD, optical density. PVD, post-vaccination days and Dpi, days post-inoculation. Error
bars indicate the mean ± SEM. Statistically significant differences between vaccine treatment groups (P value<0.05) are marked
with ��: p<0.01, ���: p<0.001, ����:p<0.0001.
https://doi.org/10.1371/journal.pone.0212431.g004
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Additionally, we evaluated the HA1 and HA3 subtypes HA-specific IgG titers in BALFs
samples. While not statistically significant, vaccinated animals achieved a greater antibody
titer at the two necropsy points of the 2nd study, with increased values at 14 dpi (Fig 4C and
4D). The difference encountered was greater for antibodies against the HA3 subtype among
groups and, in a higher rate, likely due to the fact that an H3 virus was used for the challenge.
None of the pigs vaccinated with pCMV-CTLA4-Ig (empty plasmid) raised antibodies
against H3 subtype before or after the challenge against SwH3N2 (S1 Table).
To further evaluate whether antibodies obtained from seronegative pigs (Study I) could
inhibit the attachment of the virus to the chicken red blood cells (RBCs), an HAI assay against
the challenged virus was carried out. Albeit only detecting HAI activity at 7 dpi, results dis-
played in Fig 5 suggest that all swine from the vaccinated group had significantly higher detect-
able inhibition of the hemagglutination (HI) than the non-vaccinated pigs (p<0.05). None of
the pigs vaccinated with pCMV-CTLA4-Ig (empty plasmid) could inhibit the hemagglutina-
tion of SwH3N2 (S1 Table).
Virus detection in BALFs
BALFs collected in the second study were also used to assess whether at 7 dpi and 14 dpi SIV
RNA could be detected in the respiratory tract of the lungs. While no viral RNA could be
detected at 14 dpi in any of the vaccinated pigs, differences between groups were evident at 7
dpi. Influenza virus RNA could not be detected in any of the BALFs collected from the
Fig 5. HAI activity at 7 dpi against SwH3N2 in sera from seronegative pigs (Study 1). HI titer obtained with sera
from unvaccinated (Group A) and vaccinated (Group B) pigs, at 7 dpi against the SwH3N2. White circles designate
group A (unvaccinated group), and black squares designate group B (pCMV-CTLA4-Ig-NG34 vaccinated group). HI:
Inhibition of the hemagglutination. Error bars indicate the mean ± SEM and statistically significant differences
between vaccine treatment groups (P value<0.05) are marked with �:p<0.05.
https://doi.org/10.1371/journal.pone.0212431.g005
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vaccinated pigs. In contrast, BALFs from two out of the three non-vaccinated pigs were posi-
tive for SIV RNA (Fig 6), demonstrating a clearance of viral RNA in the respiratory airways
from the pCMV-CTLA4-Ig-NG34 vaccinated pigs.
Data gathered from the complementary study showed that none of the three pigs vaccinated
with pCMV-CTLA4-Ig (empty plasmid) cleared the infection in the lung (S1 Table).
Discussion
Conserved peptides are highly desirable vaccine antigens/candidates for various reasons [36],
particularly with regard to safety and ease of production. NG34, the peptide antigen used in
this study, is relatively conserved and, as we reported previously [25], it consists of both a B
and T cell epitope. For this dual role of the peptide fomenting both humoral and cellular
responses in conventional pigs and the demonstrated in vitro cross-protective immune reac-
tion [25], we are seeking new strategies to present the antigen in a formulation that can poten-
tiate the immune response and confer protection against influenza virus infection. For this
purpose, NF-34 was modified to NG34. Immunization of mice with this modified HA-peptide
(NG34) elicited sustained antibodies with strong neutralizing capacity [37]. Moreover, by
cloning NG34 into the pCMV-CTLA4-Ig plasmid, our intention was to target the antigen pre-
senting cells with the objective to induce an enhanced immune response. CTLA4 was chosen
due to its described adjuvant like role at low doses as it delivers fused antigens to antigen-
Fig 6. Influenza viral RNA detection in BALFs performed by RT-qPCR. GEC per mL values obtained in BALFs
samples, obtained from MDA positive animals (Study 2), from unvaccinated (Group A) or vaccinated (Group B) pigs
at 7 dpi, corresponding to necropsy day. White circles designate group A (unvaccinated group), and black squares
designate group B (pCMV-CTLA4-Ig-NG34 vaccinated group). Dashed lines indicate the detection limit of the assay:
1.24 log10GEC/mL.
https://doi.org/10.1371/journal.pone.0212431.g006
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presenting-cells (APCs) [38]. Data reported in mice [38] indicated that targeting antigens to
antigen presenting cells (APCs) by means of CTLA4 increased both the humoral and the cellu-
lar responses. The role of CTLA4-Ig as an adjuvant has also been reported in other studies
including a model of asthma [39]. Although it has been described that IgG2a production is
predominant after DNA immunization [40], mice immunized with DNA-CTLA4-Ig generated
enhanced levels of distinct IgG subclasses (IgG1, IgG2a, IgG2b), with a predominance of the
IgG1 subtype [38]. This suggests that CTLA4 might have caused a non-specific change in the
immune response, possibly by a direct stimulation of APCs.
An intradermal delivery approach was chosen for vaccine prototype delivery mainly owing
to a large number of studies [41–43] warranting higher antibody titers by this method in com-
parison to gene injection into skeletal muscles. Furthermore, using this approach we facilitated
DNA uptake by skin-associated-lymphoid tissue that may play a role in inducing cytotoxic
T cells against viruses or intracellular pathogens [42]. We used the DNA vaccine delivery
approach first described by [44] which was previously applied also using another influenza
DNA vaccine in pigs with challenge [45]. Optimal influenza DNA plasmid doses (moles) were
identified and suggested using this delivery method in pigs [27]. Using the same delivery
method in pigs but another multivalent influenza DNA vaccine we also were able to break
MDA and protect pigs from influenza challenge. Since the DNA vaccine and the challenge
strain (H1N1psm2009) were different, we cannot compare. However, the influenza DNA stud-
ies both suggest that naked DNA vaccine seems all very powerful in protecting pigs from heter-
ologous influenza strains of both H1N1 and H3N2. Similar results have been consistently
reported by others using different influenza DNA and delivery methods [46,47].
Introduction of the NG34 peptide sequence into plasmid together with CTLA4 further
improved the immunogenicity and protective potential of the peptide-based vaccine previ-
ously reported by our group [25]. Moreover, seeing the complementary study data using
pCMV-CTA4-Ig it is evident that the combination of CTLA4 with NG34 is fundamental.
An additional DNA adjuvant effect may be obtained using the Diluvac diluent containing
Tocopherol [48]. Vaccinated animals completely eliminated virus from the lung within 7 days
after challenge as demonstrated from BALFs samples collected from seropositive pigs. Addi-
tionally, in seronegative vaccinated animals, viral shedding was also reduced to basic levels
within 5 to 7 days after infection, suggesting that transmission of the virus could greatly be
reduced with the vaccine approach used. Interestingly, vaccinated MDA positive could also
reduce virus replication and shedding, suggesting that pCMV-CTLA4-Ig-NG34 vaccine could
overcome a possible inhibition/delay in inducing an active antibody and/or cellular immune
response [19,27]. The virus clearing effects could apparently be linked to CTLA4-Ig vaccina-
tion that is involved in IgG1 activity promoting Th2 response, in a possible transportation of
the antigens in lymphoid organs [49] and in an increase of the B cell and T cell response [38].
In addition, elevated levels of anti-HA specific antibodies at 35 PVD and 7days after a H3N2
inoculation in the vaccinated pigs might have played a role in the elimination of the heterolo-
gous challenged virus. Additionally, these antibodies potently inhibited the hemagglutination
activity of the challenged virus at 7 dpi. Moreover and as reported in [25] vaccination induced
and maintained antibody cross-reactive response against H3N2 and H1N1 subtype. Further-
more, a tendency of a higher IgG titer in BALFs against H3N2 and H1N1 subtypes was
observed in the vaccinated MDA animals compared to the non-vaccinated ones.
Clinical signs and lung lesions were similar between groups. However, in the first study,
more animals from the vaccinated groups had fever than the animals from the unvaccinated
group. Likewise, there was one seropositive pig from the unvaccinated group (2nd study, ani-
mal 11) that cleared the virus at 7 dpi, at least based on viral RNA presence in BALFs samples.
This animal coincided to have had the highest MDA levels of the group at the onset of the
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experiment. Besides, due to the small number of samples studied for SIV RNA and antibody
titers in BALFs, no statistical analyses were performed.
In summary, intradermal application of pCMV-CTLA4-Ig-NG34 DNA vaccine might rep-
resent a potential alternative to combat SIVs and could overcome MDA-associated blockage
of the virus secretion. We anticipate that reducing/blocking/eliminating the influenza virus
shedding after infection is crucial for concomitant transmission to indirect naïve contact
pigs. Nonetheless, more studies are indispensable (with larger groups) and might be mainly
addressed to examine whether the presented formulation is also capable of promoting a solid
response against other widely circulating swine influenza subtypes.
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